Trifarotene Patent Expiration
Trifarotene is Used for treating acne vulgaris by activating RARgamma receptor topically. It was first introduced by Galderma Laboratories Lp
Trifarotene Patents
Given below is the list of patents protecting Trifarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aklief | US7807708 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | Jul 19, 2031 | Galderma Labs Lp |
| Aklief | US8227507 | Ligands that modulate RAR receptors | Dec 21, 2025 | Galderma Labs Lp |
| Aklief | US8470871 | Ligands that modulate RAR receptors | Dec 21, 2025 | Galderma Labs Lp |
| Aklief | US9084778 | Topical compositions containing a retinoid of the oil-in-water emulsion type | May 30, 2033 | Galderma Labs Lp |
| Aklief | US9498465 | Topical compositions in the form of a gel containing a particular solubilized retinoid | May 30, 2033 | Galderma Labs Lp |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳